Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T
On February 23, 2026, Gilead agreed to acquire Arcellx in
Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case
Abu Dhabi’s push to become a global life-sciences hub has
Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?
On February 9, Eli Lilly agreed to buy Orna Therapeutics
The FDA wants to “pre-check” factories before the medicine exists
On February 1, 2026, the U.S. Food and Drug Administration
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear
On a cold Tuesday in early January, Amgen quietly made
Obesity’s next arms race: staying power, not just weight loss
The GLP-1 era has changed what patients and investors think
Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier
On January 12, 2026, Novartis wrote a large cheque for
Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines
The pandemic made vaccines noisy. This acquisition is a bet
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
On December 22, 2025, the U.S. Food and Drug Administration
Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?
With a $130m Series B, the startup is betting that
From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins
The first wave of “milk without cows” promised more sustainable
When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials
Regulators have just qualified an AI system to score liver
The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here
A new generation of biotech start-ups is trying to “rejuvenate”
From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care
When a three-year-old from California flies to Manchester for a
A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong
Lonvi Biosciences says its procyanidin C1 capsule could, one day,
A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see
Early data from a tiny trial suggest that a single
The explainable aging clock regulators might actually like
A new bioRxiv preprint introduces ACE—Aging Cell Embeddings—an explainable, deep-generative
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
As the GLP-1 gold rush enters its most aggressive phase,
Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause
Standfirst: A hospitalised patient with a Hy’s-law-like profile has forced
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Late on Monday night in California — 10:30 p.m. PT
The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech
Lila’s Nvidia-backed raise is about more than money. It is
AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity
AstraZeneca has inked a deal worth “up to” $555 million
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
Pfizer has rejoined the weight-loss race with a $4.9bn move
Dermatology’s next play: bispecifics that shut down OX40L and TNF
Pairing a T-cell co-stimulatory brake with an inflammatory workhorse is
